ArticleCancers2024

Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups.

Susana Vives et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.